Financial results - PROVET PHARM SRL

Financial Summary - Provet Pharm Srl
Unique identification code: 15191081
Registration number: J18/65/2003
Nace: 7500
Sales - Ron
254.441
Net Profit - Ron
28.244
Employee
2
The most important financial indicators for the company Provet Pharm Srl - Unique Identification Number 15191081: sales in 2023 was 254.441 euro, registering a net profit of 28.244 euro and having an average number of 2 employees. Firma isi desfasoara activitatea in domeniul Activitati veterinare having the NACE code 7500.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Provet Pharm Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 31.644 19.315 17.245 14.575 27.345 89.358 98.040 137.393 219.433 254.441
Total Income - EUR 31.647 19.315 25.159 22.676 48.835 89.359 98.613 142.302 219.442 257.127
Total Expenses - EUR 23.862 20.374 24.163 20.557 42.494 81.884 77.982 113.316 187.838 226.312
Gross Profit/Loss - EUR 7.786 -1.059 996 2.118 6.341 7.475 20.631 28.986 31.605 30.816
Net Profit/Loss - EUR 6.836 -1.638 824 260 5.852 6.582 19.683 28.016 29.147 28.244
Employees 2 2 2 2 3 3 5 4 3 2
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 16.3%, from 219.433 euro in the year 2022, to 254.441 euro in 2023. The Net Profit decreased by -814 euro, from 29.147 euro in 2022, to 28.244 in the last year.

Check the financial reports for the company - Provet Pharm Srl

Rating financiar

Financial Rating -
Provet Pharm Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Provet Pharm Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Provet Pharm Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Provet Pharm Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Provet Pharm Srl - CUI 15191081

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 73.184 67.750 66.577 139.635 173.542 164.992 157.162 215.166 199.742 196.112
Current Assets 31.247 33.152 22.507 11.861 16.108 10.137 26.523 58.876 50.219 48.454
Inventories 467 1.592 477 87 513 8 123 4.803 9.717 7.277
Receivables 9.955 9.924 10.682 10.909 10.190 9.055 10.622 19.551 21.615 34.651
Cash 20.825 21.637 11.348 865 5.406 1.075 15.777 34.522 18.887 6.526
Shareholders Funds 103.791 103.019 80.524 71.322 75.865 80.977 113.140 124.745 154.279 182.055
Social Capital 45 45 45 44 43 42 41 40 41 40
Debts 31.705 27.907 45.179 115.420 128.353 94.152 84.560 149.297 95.682 62.512
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "7500 - 7500"
CAEN Financial Year 7500
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 48.454 euro in 2023 which includes Inventories of 7.277 euro, Receivables of 34.651 euro and cash availability of 6.526 euro.
The company's Equity was valued at 182.055 euro, while total Liabilities amounted to 62.512 euro. Equity increased by 28.244 euro, from 154.279 euro in 2022, to 182.055 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Provet Pharm Srl

Comments - Provet Pharm Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.